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Abstract
Glutamine is conditionally essential in cancer cells, being utilized as a carbon and nitrogen source for
macromolecule production, as well as for anaplerotic reactions fuelling the tricarboxylic acid (TCA) cycle. In this
study, we demonstrated that the glutamine transporter ASCT2 (SLC1A5) is highly expressed in prostate cancer
patient samples. Using LNCaP and PC-3 prostate cancer cell lines, we showed that chemical or shRNA-mediated
inhibition of ASCT2 function in vitro decreases glutamine uptake, cell cycle progression through E2F transcription
factors, mTORC1 pathway activation and cell growth. Chemical inhibition also reduces basal oxygen consumption
and fatty acid synthesis, showing that downstream metabolic function is reliant on ASCT2-mediated glutamine
uptake. Furthermore, shRNA knockdown of ASCT2 in PC-3 cell xenografts significantly inhibits tumour growth
and metastasis in vivo, associated with the down-regulation of E2F cell cycle pathway proteins. In conclusion,
ASCT2-mediated glutamine uptake is essential for multiple pathways regulating the cell cycle and cell growth,
and is therefore a putative therapeutic target in prostate cancer.
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Glutamine is the most abundant amino acid in plasma,
functioning as a critical source of nitrogen and carbon in
cells. The metabolic shift in cancer, however, imparts a
new ability to the cells to utilize glutamine as an alter-
native fuel source to glucose for the tricarboxylic acid
(TCA) cycle, and as a source of fatty acid production
through reductive carboxylation [1–3]. Many of these
changes in glutamine metabolism result directly from
oncogenic transformation, such as Myc amplification
[4–6], commonly seen in prostate cancer [7].
Another important role for amino acids is to control
signalling through the nutrient sensor mTORC1. The
tumour suppressor gene, PTEN, is commonly mutated
or deleted in prostate cancer [8], leading to up-regulation
of the PI3K–Akt–mTORC1 signalling pathway. The
amount of intracellular amino acids, such as leucine,
determines the activity of mTORC1 through Rag com-
plexes on the lysosome surface [9–13]. In combination
with leucine, glutamine has also been shown to be criti-
cal formTORC1 signalling by enhancing glutaminolysis
and α-ketoglutarate production [14]. This link is further
supported by the role of glutamine in facilitating leucine
transport [15] and the feedback generated by activa-
tion of mTORC1, which promotes glutaminolysis in
cancer [3].
The major glutamine transporter in cancer cells is
alanine–serine–cysteine transporter-2 (ASCT2;
SLC1A5) [26–28]. ASCT2 is a Na+-dependent, broad-
scope neutral amino acid exchanger that belongs to
solute carrier (SLC) family-1, which mediates the
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obligatory exchange of substrate amino acids, including
alanine, serine, cysteine, threonine, glutamine and
asparagine [16]. ASCT2 is expressed in the normal
prostate and in prostate cancer [17]. Previous studies
have shown that ASCT2 function is important for
cancer cell growth in melanoma [18], acute myeloid
leukaemia [19], lung cancer [20], neuroblastoma [21]
and pancreatic ductal carcinoma [22].
In this study we showed that ASCT2 expression is
increased in prostate cancer patient samples, and that
knockdown inhibits cell cycle progression, prostate can-
cer growth and spontaneous metastasis in vivo. ASCT2
chemical inhibitors also suppressed glutamine transport,
cell growth and glutamine metabolism in vitro. Our
study suggests that compounds targeting ASCT2 may
provide novel therapeutics for prostate cancer.
Materials and methods
For additional materials and methods, please see the
online Supplementary material.
Patient specimens
Prostate cancer specimens from radical prostatectomy
(n= 194) were obtained from the Vancouver Prostate
Centre Tissue Bank (http://www.prostatecentre.com/
our-research/core-facilities/biorepository). This project
was approved by the institutional review boards at the
University of British Columbia (Vancouver, Canada)
and the CHUQ Research Centre (Québec, Canada).
Written informed consent was obtained from all par-
ticipants. The haematoxylin and eosin (H&E)-stained
slides were reviewed and desired areas were identified
on paraffin blocks. Tissue microarrays (TMAs) were
manually constructed (Beecher Instruments, MD, USA)
by punching duplicate cores of 1mm for each sample,
with quantitative analysis calculated from individual
cores (individual Gleason scores) or the average of
duplicate cores (NHT TMA analysis).
TMA immunohistochemistry
TMA staining was conducted using a Ventana auto-
stainer, model Discover XT™, with an enzyme-labelled
biotin–streptavidin system and solvent-resistant DAB
Map kit, using a 1:4000 dilution of rabbit anti-SLC1A5
(HPA035240). Staining was graded by a pathologist
(LF), using a semi-quantitative, four-point scale, in
which 0 represents no staining, 1 faint or focal staining,
2 moderate intensity in at least a quarter of neoplastic
cells, and 3 intense staining in the majority of neoplastic
cells. Examples of the staining are shown in Figure S1B
(see supplementary material).
Cell culture and uptake assay
Human prostate cancer cell lines LNCaP-FGC, PC-3
and DU145 were purchased from ATCC (Rockville,
MD, USA). LNCaP cells had been passaged directly
from original low-passage stocks (2009), and we con-
firmed PC-3, LNCaP and DU145 cell identity by STR
profiling in 2010 and 2014 (Cellbank, Sydney). Cells
were cultured in RPMI 1640 medium containing 10%
v/v fetal bovine serum (FBS), penicillin–streptomycin
solution and 1mM sodium pyruvate. Cells were main-
tained at 37 ∘C in an atmosphere containing 5%
CO2. Chemicals were diluted as follows, with control
wells treated with the appropriate vehicle controls:
H-Ser(Bzl)-OH (BenSer; Bachem; diluted in H2O);
l-γ-glutamyl-p-nitroanilide (GPNA; MP Biochemicals;
diluted in H2O); bicalutamide (Astra Zeneca; diluted
in DMSO). The [3H]-L-leucine and [3H]-L-glutamine
uptake assays were performed as detailed previously
[18,32].
Knockdown of ASCT2
ASCT2 shRNA knockdown was performed as pre-
viously described [18]. Two different shRNAs for
ASCT2 were used in this study (Sigma): shASCT2#1
(CCGGGCTGCTTATCCGCTTCTTCAACTCGAGTT
GAAGAAGCGGATAAGCAGCTTTTTG) and shASC
T2#2 (CCGGCTGGATTATGAGGAATGGATACTCG
A GTATCCATTCCTCATAATCCAGTTTTTG).
Gene expression analysis
PC-3 cells were incubated in the presence or absence
of GPNA or BenSer for 48 h, the cells were harvested
and total RNA was extracted from them using Trizol.
RNA quality was confirmed (RIN values 9.8–10), using
RNA 6000 Nano Chips on an Agilent 2100 Bioanal-
yser (Agilent Technologies). Libraries were prepared
using TruSeq Stranded Total RNA kit (Illumina, San
Diego, CA, USA) and paired-end sequencing was per-
formed on an Illumina HiSeq 2500 at the Kinghorn Can-
cer Centre (Sydney). Paired-end RNA-sequencing reads
were trimmed and mapped to annotated human genome
(hg19/GRCh37.p13), using Tophat2 with default set-
tings. For each gene, the number of reads were counted
and normalized to the library size. The threshold for
expression was set at five reads in at least one experi-
mental group. Exact tests were applied to compare dif-
ferences in the means of read-counts from four repli-
cates between the treated and untreated groups. The
gene expression levels were estimated counts/million
reads (CPM). The National Center for Biotechnol-
ogy Information Gene Expression Omnibus number for
mRNA sequencing datasets described in this study is
GSE65112.
PC-3–luc xenografts and bioluminescence imaging
Athymic (nu/nu) male nude mice (Animal Resource
Centre, Perth, Australia), aged 6–8 weeks, were housed
in a specific pathogen-free facility, in accordance with
the University of Sydney animal ethics committee
guidelines. Mice were anaesthetized via 2% isoflurane
inhalation and received subcutaneous (s.c.) injections of
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1× 106 PC-3–luc cells resuspended in 100ml Hanks’
balanced salt solution (HBSS). Xenografts were trans-
planted in both the right and left ventral flanks of
mice, as detailed previously [30]. Tumour growth was
monitored via bioluminescence imaging performed 48 h
following cell implantation and biweekly thereafter for
32 days. During the experiments, two shASCT2 mice
were dead 4 days after injection, due to fighting; they
were not included in the analyses. Anaesthetized mice
received intraperitoneal (i.p.) injections of D-luciferin
substrate (150mg/kg in DPBS; Gold Biotechnology)
and images were acquired after a 15min interval, using
the Xenogen in vivo imaging system (IVIS) Lumina II
(Caliper Life Science, MA, USA). Regions of interest
were determined using Living Image software (Caliper
Life Science) and quantified in photons/s (p/s). After
32 days, the animals were sacrificed following the final
imaging time point. Livers and lungs were removed
for IVIS-Lumina II analysis to detect spontaneous
metastases. After being imaged and weighed, tumours
were collected in either Trizol for RNA analysis or
lysis buffer for western blotting analysis, or fixed in
10% v/v neutral buffered formalin for sectioning and
immunostaining.
Statistical analysis
Data are expressed as mean±SEM. All experiments
were performed with at least three replicate experiments
and analysed using a Mann–Whitney U-test or one-way
ANOVA in GraphPad Prism v. 6.MTT assay and tumour
growth curve analysis used the two-way ANOVA test.
Fisher’s exact test was used in tumour metastasis analy-
sis. All statistical tests were two-sided.
Results
ASCT2 expression is increased in prostate cancer
To determine whether ASCT2 expression is increased
in prostate cancer compared to normal tissue, we com-
pared patient-matched TCGA mRNA expression data
for normal prostate versus prostate cancer (Figure 1A).
There was a significant increase in ASCT2 expression
in tumour samples compared to normal (pairwise t-test,
p= 0.025), with 24/36 patients showing increased
tumour ASCT2 levels compared to patient-matched
normal prostate tissue (χ2 test, p= 0.046). Analysis
of Oncomine datasets showed significant increases in
ASCT2 expression (p< 0.05) in seven prostate can-
cer datasets (Table 1). To determine ASCT2 protein
levels, we performed immunohistochemical staining
on a human prostate cancer tissue microarray (TMA;
Figure 1B). At all stages of prostate cancer, ASCT2
protein was detected in the membrane of the prostate
epithelial cells, but not in the cytoplasm (see supplemen-
tary material, Figure S1A). There were no significant
differences in expression between Gleason grades in
either the TMAor the TCGA dataset (see supplementary
material, Figure S1B, C). Comparing untreated with
patients undergoing neoadjuvant hormone therapy
(NHT), a significant decrease in ASCT2 protein expres-
sion was observed during 1–6 and 7–12 months of
treatment (p= 0.04; p< 0.001; Figure 1C). This sup-
ports previous data showing that ASCT2 expression is
regulated by the androgen receptor [23]. Interestingly,
ASCT2 expression significantly increased in patients
with recurrent prostate cancer (p< 0.001; Figure 1C),
indicating either re-activation of androgen receptor
signalling or that other signalling pathways might
up-regulate ASCT2 expression upon disease recur-
rence. Analysis of an LNCaP xenograft model [24]
at various stages precastration (intact), postcastration
during regression, at the nadir of PSA, and in recur-
rent and castration-resistant prostate cancer (CRPC)
further confirmed this dynamic regulation of ASCT2
expression. ASCT2 expression decreased significantly
post-castration (regression and nadir), before increas-
ing in recurrent and CRPC, where ASCT2 expression
was no longer significantly different from intact ASCT2
levels (Figure 1D). These human and xenograft data sug-
gest that ASCT2 levelsmay be important, both in the pri-
mary tumour and during tumour recurrence and CRPC.
Inhibition of ASCT2 suppresses prostate cancer cell
growth
Analysis of ASCT2 protein showed high expression in
both LNCaP and PC-3 cells, with lower levels detected
in DU145 cells (Figure 2A). Addition of the ASCT2
competitive inhibitor benzylserine (BenSer; see sup-
plementary material, Figure S2A) [25] significantly
reduced both glutamine and leucine uptake in LNCaP,
PC-3 and DU145 cells (Figure 2B, C). Leucine uptake
inhibition occurs due to exchange of glutamine for
leucine by L-type amino acid transporter 1 (LAT1;
SLC7A5), but may also be through direct LAT1 inhi-
bition [15]. Inhibition of androgen receptor signalling
by bicalutamide also significantly reduced glutamine
uptake in androgen-sensitive LNCaP cells, but not
androgen-insensitive PC-3 cells (see supplementary
material, Figure S2B, C), confirming that AR signalling
regulates ASCT2 levels [23] and ASCT2-mediated
glutamine transport. After 3 days of treatment with
BenSer, cell growth was significantly decreased in
LNCaP, PC-3 and DU145 cells (Figure 2D). We
have previously shown that LAT1 inhibition affects
the cell cycle through E2F-regulated cell cycle pro-
teins CDK1, CDC20 and UBE2C [23]. These three
cell cycle-regulatory proteins are also significantly
increased in prostate cancer metastasis [23]. CDK1,
CDC20 and UBE2C exhibited decreased expression
after BenSer treatment (Figure 2E).
Inhibition of ASCT2 suppresses glutamine
metabolism in prostate cancer
As leucine and glutamine are involved in the activa-
tion of mTORC1 signalling [14,26,27], we examined
© 2015 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2015; 236: 278–289
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org.uk www.thejournalofpathology.com
Regulation of glutamine transport in prostate cancer 281
Figure 1. ASCT2 is androgen receptor-regulated and expressed in prostate cancer patient samples and xenografts. (A) ASCT2 mRNA
expression in matched prostate cancer samples compared to adjacent normal prostate from the TCGA dataset (data are mean± SEM; paired
t-test; n= 36). (B) Representative images of ASCT2 protein expression in prostate cancer patient samples from Gleason grades 3, 4 and 5
and after neoadjuvant hormone therapy (NHT) treatment following an interval of 1–6 months, 7–12 months and in recurrent cancer; scale
bar= 100 μm. (C) Immunohistochemical scoring of ASCT2 expression in patient cohorts before (n= 46) and after NHT treatment for 1–6
months (n= 54), 7–12 months (n= 76) and recurrent cancer (n= 32); data are mean± SEM; Mann–Whitney U-test. (D) Microarray analysis
of ASCT2 mRNA expression from LNCaP xenograft tumours harvested from non-castrated mice (intact; n= 10), post-castration regressing
tumours (regressing; n= 6), at PSA nadir after castration (nadir; n= 10), after recurrent prostate cancer had developed (recurrent; n= 6)
and castration-resistant prostate cancer (CRPC; n= 13); data are mean± SEM; Mann–Whitney U-test; *p< 0.05, ** p< 0.01, *** p< 0.001
Table 1. SLC1A5/ASCT2 expression in Oncomine datasets
Dataset Fold change p PCa samples (n)
Su multi-cancer 2⋅36 1.67E-09 26
Singh prostate 2⋅106 3.24E-04 52
Ramaswamy multi-cancer 2⋅087 7.44E-04 10
Wallace prostate 1⋅745 5.11E-04 69
Magee prostate 1⋅518 0.018 8
Bittner multi-cancer 1⋅459 3.64E-12 59
Welsh prostate 1⋅399 7.00E-03 25
T389 phosphorylation of p70S6K, a downstream
target of mTORC1. BenSer reduced the phosphory-
lation of p70S6K in PC-3 cells, but not in LNCaP
cells (Figure 2F). Utilizing another ASCT2 inhibitor,
l-γ-glutamyl-p-nitroanilide (GPNA; see supplementary
material, Figure S2D)[28], confirmed that glutamine
deprivation inhibits the mTORC1 pathway in PC-3
cells, but not LNCaP cells (Figure 2F). These data
suggest that mechanisms other than mTORC1 must
also contribute to regulate cell growth in prostate
cancer.
The majority of intracellular glutamine is converted
into glutamate, which can be utilized by the TCA cycle
for ATP and fatty acid production, or exported from
the cell by xCT (SLC7A11) in exchange for cystine,
thereby contributing to glutathione production and
protection against oxidative stress. Alternatively,
glutamine acts as a nitrogen and carbon donor for
macromolecular synthesis, including nucleotides and
non-essential amino acids/proteins. We therefore set
out to determine how changes in intracellular glutamine
affect these downstream pathways. Using the Seahorse
flux analyser, BenSer or GPNA treatment resulted in a
reduction in basal oxygen consumption rates (OCRs)
compared to control in LNCaP and PC-3 cells (see
supplementary material, Figure S2E, F). GPNA, but
not BenSer, significantly reduced basal OCR in both
LNCaP and PC-3 cells (Figure 3A, B). However, this
reduction in OCR did not appear to result directly from
glutamine usage, as there was no significant reduc-
tion in oxidized 14C-labelled glutamine in either cell
line after BenSer or GPNA (Figure 3C, D), despite
lower 14C-glutamine uptake (see supplementary mate-
rial, Figure S2G, H). Lipid synthesis from glutamine,
however, was significantly decreased in LNCaP cells
(Figure 3E), but not in PC-3 cells (Figure 3F). These
data suggest that LNCaP cells directly utilize glutamine
for fatty acid synthesis, while PC-3 cells may utilize
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Figure 2. Inhibition of ASCT2-mediated glutamine transport in prostate cancer cell lines. (A) ASCT2 protein was detected by western blotting
in LNCaP, PC-3 and DU145 cell lines. (B, C) Effect of BenSer (10mM) on glutamine (B) and leucine (C) transport in LNCaP, PC-3 and DU145
cell lines was assessed. (D) Cell growth of LNCaP, PC-3 and DU145 was examined in the presence of BenSer. (E) CDK1, CDC20 and UBE2C
expressions were detected by western blotting in LNCaP and PC-3 cells in the presence of BenSer. (F) mTORC1 pathway activation (p-p70S6K)
was analysed in LNCaP and PC-3 cells after BenSer or GPNA treatment after 2 h. (B, C) Data are mean± SEM (n≥ 3); Mann–Whitney U-test
was used to analyse data. (D) Data are mean± SEM (n≥ 3); two-way ANOVA test was used to analyse data; *p< 0.05, ** p< 0.01, *** p< 0.001
glutamine for other pathways, including exchange for
leucine (Figure 2C) to activate mTORC1 signalling
(Figure 2F), which indirectly affects mitochondrial
respiration.
To further investigate lipid homeostasis, we mea-
sured the levels of cellular phospholipids and neutral
lipids. Lipid content analysis of LNCaP cells revealed
that GPNA significantly reduced the cellular level of
phospholipids (Figure 3G) and BenSer and GPNA
reduced the neutral lipids (Figure 3I) as well as lipid
droplet number (Figure 3K). Notably, the magnitude
of inhibition by BenSer and GPNA was similar to
thast of 5-(tetradecyloxy)-2-furoic acid (TOFA), which
inhibits the rate-limiting enzyme of fatty acid synthesis,
acetyl-CoA carboxylase (Figure 3G, I, K). A significant
decrease of phospholipids was also observed in PC-3
cells (Figure 3H); however, there were no significant
decreases in neutral lipids (Figure 3J) or lipid droplet
numbers (Figure 3L). Taken together, pharmacological
inhibition of ASCT2 provoked cell line-specific effects
on the flux of glutamine as a fuel source, yet ultimately
led to reduced OCR and cellular lipid levels in both
prostate cancer cell lines. However, neither BenSer nor
GPNA led to increased levels of reactive oxygen species
(ROS; see supplementary material, Figure S2I).
Global effects of BenSer or GPNA inhibition in PC-3
cells
To determine the global effects of ASCT2 inhibition,
we used next-generation sequencing to determine
mRNA expression changes in PC-3 cells treated with
BenSer or GPNA for 48 h. Analysis of genes signif-
icantly (p< 0.05) up- or down-regulated by GPNA
(see supplementary material, Table S1) compared to
control showed a substantial overlap (up-regulated,
45.1%; down-regulated, 49.7%) with BenSer gene
expression, highlighting common targets of ASCT2
(Figure 4A). BenSer appears to have additional
non-ASCT2-mediated affects, with more genes showing
significant up- and down-regulation (see supplementary
material, Table S2) compared to GPNA (Figure 4A).
This is not surprising, since BenSer has been shown to
inhibit both ASCT2 and LAT1 function in oocytes [18].
Gene set enrichment analysis (GSEA) using Gene
Ontology categories showed significant enrichment in
control compared to GPNA for RNA and DNA pro-
cessing and metabolism, as well as cell cycle processes
(Figure 4B; see also supplementary material, Table S3).
Similar categories were also enriched in control com-
pared to BenSer (Figure 4C; see also supplementary
material, Table S4). Analysis of motif enrichment by
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Figure 3. Inhibition of ASCT2 affects cell metabolism in LNCaP and PC-3 cells. (A, B) Basal oxygen consumption rate (OCR) was analysed
using a SeaHorse XF Analyser in LNCaP (A) and PC-3 (B) cells pretreated with BenSer (10mM) or GPNA (1mM). (C, D) 14CO2 generated from
glutamine in LNCaP (C) and PC-3 (D) cells was determined after treatment with BenSer (10mM) or GPNA (1mM). (E, F) Lipid generated from
glutamine was analysed in LNCaP (E) and PC-3 (F) cells after treatment with BenSer (10mM) or GPNA (1mM). (G–J) Mean fluorescence
intensities of cellular phospholipids (G, H) and neutral lipids (I, J) were measured in LNCaP (G, I) and PC-3 cells (H, J) after treatment for
24 h with BenSer (10mM), GPNA (1mM) or TOFA (10 μM). (K, L) Lipid droplets were measured in LNCaP (K) and PC-3 (L) cells after treatment
with BenSer, GPNA or TOFA. (A–F) Data are mean± SEM (n≥ 3); one-way ANOVA was used to analyse data. (G–L) Data are mean± SEM
(n≈ 300 cells); one-way ANOVA was used to analyse data; *p< 0.05, ** p< 0.01, *** p< 0.001
GSEA showed a significant association with E2F tran-
scription factor motifs for control compared to either
GPNA or BenSer (Figure 4D, E; see also supplemen-
tary material, Tables S5, S6). We have previously shown
that inhibition of leucine uptake in LNCaP cells shows
similar E2F-mediated cell cycle inhibition, with a sub-
set of 122 genes down-regulated by the leucine uptake
inhibitor BCH [23]. Analysis of this 122-gene signa-
ture in control versus GPNA and BenSer showed enrich-
ment in the control group (Figure 4F, G), suggesting that
there is a common mechanism regulating gene expres-
sion after leucine starvation and glutamine starvation in
prostate cancer.
Amino acid starvation leads to up-regulation of the
stress-response transcription factor ATF4, which in
turn leads to increased expression of diverse amino
acid transporters, including ASCT2 and LAT1 [23].
ATF4 was the first (p= 1.10E-11) and sixteenth
(p= 4.21E-21) most significantly up-regulated gene
in GPNA- or BenSer-treated cells, respectively (see
supplementary material, Tables S1, S2), which was ver-
ified by RT–qPCR (see supplementary material, Figure
S3A, B). ATF4 has previously been shown to directly
transcriptionally regulate the expression of trans-
porters including ASCT2, ASCT1, xCT and SLC3A2
[23,29]. Analysis of gene sets up-regulated after GPNA
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Figure 4. RNA-seq analysis of PC-3 cells treated with BenSer or GPNA. (A) Venn diagram of genes up- or down-regulated in both BenSer-
and GPNA-treated groups. (B, C) Gene set enrichment analysis (GSEA) plot of Gene Ontology categories RNA Processing and Cell Cycle
Process in control versus GPNA (1mM; B) or BenSer (10mM; C) treatment. (D, E) GSEA plot of E2F transcription factor motif gene set in
control versus GPNA (1mM; D) or BenSer (10mM; E) treatment. (F, G) GSEA plot of BCH down-regulated gene set (from [23]) in control
versus GPNA (1mM; F) or BenSer (10mM; G) treatment groups
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inhibition showed significant enrichment for Gene
Ontology categories, including amino acid transport
(see supplementary material, Figure S3C), with signif-
icant up-regulation of transporters, including SLC1A5
(ASCT2, p= 0.020), SLC1A4 (ASCT1; p= 7.72E-5),
SLC7A11 (xCT; p= 7.02E-8), SLC38A1 (SNAT1;
p= 3.51E-5), SLC7A8 (LAT2; p= 5.63E-5), SLC3A2
(4F2hc; p= 0.041) and SLC3A1 (p= 0.005). Another
critical gene significantly increased by both GPNA
(p= 0.009) and BenSer (p= 0.0002) was EIF2AK3
(PERK), which can phosphorylate eIF2α, leading to
global protein synthesis suppression. A set of genes
that belong to eukaryotic translation initiation factor are
significantly decreased after GPNA treatment, includ-
ing EIF3B (p= 0.0003), EIF2A (p= 0.003), EIF4H
(p= 0.005), EIF5A (p= 0.009), EIF2B3 (p= 0.034),
EIF4G1 (p= 0.039), EIF2B4 (p= 0.040) and EIF2B5
(p= 0.048).
Knockdown of ASCT2 suppresses growth in prostate
cancer cells
We used lentiviral shRNA-mediated knockdown of
ASCT2 to substantiate the direct ASCT2 effects of
BenSer and GPNA in LNCaP and PC-3 cells. Two
different shRNAs decreased ASCT2 expression and
glutamine transport in LNCaP and PC-3 cells compared
to a non-targeting shRNA control (Figure 5A, B; see
also supplementary material, Figure S3D). Inhibition
using shASCT2#2 also significantly decreased leucine
uptake in both LNCaP and PC-3 cells (Figure 5C), sug-
gesting that ASCT2-transported glutamine is utilized
for leucine uptake.
LNCaP and PC-3 cells expressing shASCT2#2
showed a significant decrease in cell viability com-
pared to shControl cells (Figure 5D, E). Analysis of
BrdU incorporation (Figure 5F) and apoptosis (see
supplementary material, Figure S3E) in shASCT2#2-
expressing PC-3 cells confirmed that ASCT2 knock-
down inhibits the cell cycle rather than apoptosis.
Similar results for glutamine uptake, BrdU incorpora-
tion and apoptosis were also observed in shASCT2#1
PC-3 cells (see supplementary material, Figure S3D, F,
G). Finally, we examined mTORC1 pathway activation
by western blotting, showing reduced phosphoryla-
tion of p70S6K in PC-3 cells expressing shASCT2#2
(Figure 5G).
Knockdown of ASCT2 suppresses tumour growth
in prostate cancer xenografts
To determine whether ASCT2 function is critical for
tumour growth in vivo, PC-3 cells expressing shCon-
trol or shASCT2#2 were transduced with a lentiviral
vector co-expressing eGFP and firefly luciferase [30].
Cells were enriched to high purity on a narrow band of
highGFP expression, resulting in similar GFP/luciferase
expression in each shControl and shASCT2 cell line (see
supplementary material, Figure S4A). PC-3–luc cells
were subcutaneously injected into nude mice, with sim-
ilar luciferase expression in shControl and shASCT2
tumours confirmed after 48 h (Figure 6A). Biolumines-
cence was analysed twice weekly for 32 days, showing
a significant decrease in shASCT2 tumour size by day
25 (Figure 6B).
Mice were euthanized after 32 days, due to the size
of the shControl tumours. The tumours were isolated,
photographed and weighed, with shControl tumours
being significantly larger than shASCT2 tumours
(Figure 6C, D; p< 0.001). Western blots of xenograft
tumours showed that phosphorylation of p70S6K was
decreased in shASCT2 tumours compared to shCon-
trol tumours (Figure 6E). Analysis of E2F2, CDK1,
CDC20, UBE2C and the proliferation biomarker Ki67
in xenograft sections showed consistently lower levels
in the shASCT2 tumours (Figure 6F). There were no
changes in cleaved caspase 3 levels (see supplementary
material, Figure S4B).
Micrometastases were detected by isolation and ex
vivo bioluminescence analysis of organs immediately
after euthanasia (see supplementary material, Figure
S4C). Analysis of shControl mice showed that nine of
10 had metastases in the liver and four of 10 in the
lung, while shASCT2 mice showed that four of nine
had metastases in the liver, with no lung metastases
(p= 0.004; Figure 6G).Metastatic bioluminescence bur-
den in the liver and lung also showed a significant
decrease in shASCT2 xenografted mice (Figure 6H).
Discussion
ASCT2 can be regulated by multiple transcription fac-
tors, includingMyc [6], Rb/E2F [31], androgen receptor
[23] andATF4 [21,23]. This permits similar ASCT2 pro-
tein expression in both androgen-dependent (LNCaP)
and androgen-independent (PC-3) prostate cancer cell
lines, and facilitates sufficient glutamine for cell growth.
Our patient and LNCaP xenograft data confirmed that
androgen receptor regulation of ASCT2 contributes to
its expression in untreated/primary cancer and that under
androgen-deprivation therapy, ASCT2 levels decrease.
Similar to other androgen receptor- and ATF4-regulated
genes [23], re-expression of ASCT2 was observed in
recurrent disease. Importantly, ATF4 levels are signifi-
cantly increased in androgen-independent prostate can-
cer metastasis compared to primary cancer (2.25-fold;
p= 3.82E-7) [23], suggesting that activation of ATF4
transcriptional targets is important in either metastasis
or maintenance of the metastatic tumour. Interestingly,
ASCT2 knockdown tumours showed decreased metas-
tasis in the liver and lung, although this was confounded
by the smaller primary tumours.
Blocking ASCT2 using either chemical or genetic
means reduced cell proliferation and cell cycle in both
LNCaP and PC-3 cell lines. This coincided not only
with reduced glutamine levels but also with a reduction
in the essential amino acid leucine, likely through
LAT1-mediated exchange for leucine. Although knock-
down of ASCT2 resulted in similar glutamine uptake
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Figure 5. ASCT2 is required for prostate cancer cell proliferation. (A) Analysis of ASCT2 protein after shRNA knockdown in LNCAP or PC-3
cells using shASCT2#1 or shASCT2#2. (B, C) Analysis of glutamine (B) or leucine (C) uptake in LNCaP or PC-3 cells after shASCT2 knockdown.
(D, E) LNCaP (D) and PC-3 (E) cell growth after shASCT2#2 knockdown was analysed by MTT assay. (F, G) Cell cycle progression (BrdU
incorporation; F) and mTORC1 pathway activation (p-p70S6K; G) was analysed after shASCT2#2 knockdown in PC-3 cells. (B, C, F) Data are
mean± SEM (n≥ 3); Mann–Whitney U-test was used to analyse data. (D, E) Data are mean± SEM (n≥ 3); significance was assessed using
two-way ANOVA; *p< 0.05, ** p< 0.01, *** p< 0.001
inhibition in LNCaP and PC-3 cells, leucine uptake was
inhibited at a higher level in PC-3 cells, coincident with
the higher LAT1 expression compared to LNCaP cells
[32], further supporting the ASCT2–LAT1 exchange
hypothesis, which subsequently leads to altered
mTORC1 signalling [15,33]. ASCT2 inhibition did
not directly alter glutamine metabolism in PC-3 cells,
suggesting that the effects on basal OCR may be due to
combined glutamine/leucine inhibition and subsequent
shut-down of energy-consuming processes, such as
protein, lipid, RNA and DNA synthesis. Previous stud-
ies have shown that mTORC1 controls mitochondrial
activity through a 4EBP-dependent translation regula-
tion [34] and mitochondrial gene expression [35]. This
mechanism is further supported by the GPNA-mediated
down-regulation of GO categories for RNA and DNA
Processing and Mitochondrial Genesets in PC-3 cells.
Analysis of glutamine metabolism in LNCaP cells,
however, showed that inhibition of ASCT2 suppresses
basal oxygen consumption, as well as TCA cycle glu-
taminolysis through complete oxidation and conversion
to lipids. LNCaP cells have low expression of LAT1
and high expression of the leucine uniporter LAT3, and
thereby are not as reliant on glutamine exchange to
maintain leucine levels. They appear more reliant on
glutamine anaplerosis than PC-3 cells.
Analysis of gene expression in PC-3 cells treated
with BenSer or GPNA showed an adaptive response
to glutamine deprivation through ATF4-mediated tran-
scription, resulting in reduced cell cycle and RNA pro-
cessing, and up-regulation of amino acid transporters in
an attempt to restore glutamine levels. Previous studies
have suggested that targeting this ATF4-mediated stress
response may provide an effective cancer therapy [36].
However, in glioblastoma, the ATF4 response to glu-
tamine deprivation directs apoptosis through NOXA and
PUMA [37]. Unlike glioblastoma, we did not observe an
increase in apoptosis in PC-3 cells after ASCT2 inhibi-
tion. These chemicals, or ASCT2 shRNA knockdown,
do not induce complete glutamine deprivation, suggest-
ing that perhaps the magnitude of glutamine deprivation,
and subsequent ATF4 activation, may be critical in driv-
ing cell fate decisions for survival or apoptosis.
High expression of ASCT2 has previously been
reported in the normal prostate [17] and many rapidly
dividing normal cells rely on ASCT2 expression for
glutamine uptake. Despite this important function
in normal cells, the ASCT2 knockout mice do not
show any obvious abnormalities in growth or survival,
making ASCT2 an attractive therapeutic target [40].
Compared to the immunosuppressive effects of directly
inhibiting mTORC1, the ASCT2 knockout mice have a
relatively mild immune phenotype involving Th1 and
Th17 lineage differentiation [40]. Despite this mild
phenotype, it will still be important to monitor immune
cells and effects on other normal cells when developing
ASCT2-targeted therapies.
Our in vivo knockdown data support the develop-
ment of ASCT2 as a therapeutic target in prostate
cancer. Since ASCT2 is androgen-regulated, one
could envisage targeting ASCT2 in either primary
or advanced prostate cancer. Importantly, our data
showed that targeting ASCT2 not only inhibited known
pathways, such as mTORC1, but also regulated the
critical metastasis-expressed, E2F-regulated, cell cycle
genes CDK1, CDC20 and UBE2C, thereby resulting
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Figure 6. ASCT2 is required for tumour growth in vivo. (A) PC-3-luc cells stably expressing shControl or shASCT2#2 were injected
subcutaneously into the right and left dorsal flanks of male nude mice; bioluminescent images are shown at days 2 and 32. (B) Tumour
growth was measured twice weekly by bioluminescence in shControl (n= 10) and shASCT2 (n= 8) mice; data are mean± SEM; significance
was assessed using two-way ANOVA; *** < 0.001. (C, D) Tumours (shControl, n= 20; shASCT2#2, n= 15) were harvested after 32 days, imaged
(C) and weighed (D). (E) Phosphorylated p70S6K was measured after shASCT2 knockdown in PC-3 xenograft. (F) Sections from shControl and
shASCT2 tumours were stained for CDK1, CDC20, UBE2C and Ki67 expression; representative images; scale bar= 100 μm. (G, H) Number (G)
and size (H) of spontaneous metastases in liver and lung were measured by bioluminescence. (B) Data are mean± SEM; significance was
assessed using two-way ANOVA. (D, H) Data are mean± SEM; Mann–Whitney U-test was used to analyse data. (G) Number of spontaneous
metastases at day 32 in shControl and shASCT2 mice was assessed using two-tailed Fisher exact test; *p< 0.05, ** p< 0.01, *** p< 0.001
in a two-pronged block of cell division. This suggests
that ASCT2-targeted therapies may be particularly
effective in advanced castration-resistant prostate
cancer. However, current ASCT2 inhibitors, such as
BenSer [38], GPNA [28] and dithiazoles [39], have
high effective concentrations, rendering them inef-
fective as putative therapeutics. The development of
new inhibitors in the low μM or nM range would be
required for further preclinical testing. This is one of
the major limitations of this current study. Addition-
ally, once a drug is developed, it would be important
to determine an appropriate clinical population and
setting that may benefit from ASCT2 targeting, using
preclinical models such as patient-derived xenografts
or explants. Further limitations surround the poten-
tial up-regulation of other glutamine transporters by
adaptive mechanisms such as ATF4 transcription; this
will need to be monitored for potential compensation
mechanisms in tumours. Finally, while glutamine is
clearly an important amino acid transported by ASCT2,
it remains to be determined what downstream effects are
caused by inhibition of other ASCT2-transported amino
acids, such as alanine, serine, cysteine, threonine or
asparagine.
In summary, we have shown that ASCT2 is the key
glutamine transporter that regulates prostate cancer pro-
liferation and metabolism. We have identified critical
cell cycle and metabolic pathways, which may provide
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new avenues for therapeutic intervention in prostate
cancer.
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